Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis

被引:0
作者
Michael S. Schechter
Natalia Sabater-Anaya
Gerry Oster
Derek Weycker
Hongsheng Wu
Emilio Arteaga-Solis
Sukirti Bagal
Lisa J. McGarry
Kate Van Brunt
Jessica Morlando Geiger
机构
[1] Children’s Hospital of Richmond at Virginia Commonwealth University,
[2] Policy Analysis Inc,undefined
[3] Vertex Pharmaceuticals Incorporated,undefined
来源
Pulmonary Therapy | 2023年 / 9卷
关键词
CFTR modulator; Claims; Elexacaftor; HCRU; Healthcare cost; Healthcare resource utilization; Ivacaftor; Tezacaftor;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:479 / 498
页数:19
相关论文
共 130 条
[1]  
Bell S(2020)The future of cystic fibrosis care: a global perspective Lancet Respir Med 8 65-124
[2]  
Mall M(2016)Cystic fibrosis Lancet 388 2519-2531
[3]  
Gutierrez H(2015)Cystic fibrosis Nat Rev Dis Primers 1 15010-431
[4]  
Macek M(2018)The burden of cystic fibrosis in the Medicaid population Clinicoecon Outcomes Res 10 423-2844
[5]  
Madge S(2021)Healthcare resource utilization and costs among children with cystic fibrosis in the United States Pediatr Pulm 56 2833-1819
[6]  
Davies J(2019)Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single N Engl J Med 381 1809-1948
[7]  
Elborn J(2019) allele Lancet 394 1940-825
[8]  
Ratjen F(2021)Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the N Engl J Med 385 815-1532
[9]  
Bell S(2021) mutation: a double-blind, randomised, phase 3 trial Am J Respir Crit Care Med 203 1522-67
[10]  
Rowe S(2023)Triple therapy for cystic fibrosis Am J Respir Crit Care Med 208 59-78